LInezolid Monitoring to MInimise Toxicity (LIMMIT1): A multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring.
Lau C, Marriott D, Bui J, Figtree M, Gould M, Chubaty A, Su Y, Adhikari S, Konecny P, Kozierowski K, Holland T, Milliken E, Akram A, Mcnamara A, Sun Y, Van Hal S, Patanwala AE, Shahabi-Sirjani A, Gray T, Yeo CY, Netluch A, Halena S, Appay M, Alameddine R, Yin F, Nguyen Q, So MY, Sandaradura I, Kim HY, Galimam S, Cerruto N, Lai T, Gilbey T, Daveson K, Reuter SE, Penm J, Alffenaar JW.
Lau C, et al. Among authors: figtree m.
Int J Antimicrob Agents. 2023 May;61(5):106783. doi: 10.1016/j.ijantimicag.2023.106783. Epub 2023 Mar 14.
Int J Antimicrob Agents. 2023.
PMID: 36921808